Effect of oxybutinine on serteralin induced sweating in patients with depression

Randomized clinical trial of the effect of oxybutinine on serteralin induced sweating in patients with depression

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201101045547N1

Enrollment

140

Registered

2011-05-16

Start date

2010-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mjor depressive disorder. Depressive episode, unspecified

Interventions

Intervention 1: ]Intervention group: oxybutinine tablet 5mg 2 times a day for 2 weeks. Intervention 2: Control group: Placebo tablets, two times a day or 2 weeks.

Treatment - Drugs

Placebo

]Intervention group: oxybutinine tablet 5mg 2 times a day for 2 weeks

Control group: Placebo tablets, two times a day or 2 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with major depressive disorder according to diagnostic and statistical manual IV- TR criteria that are using serteraline as a treatment and have sweating as side effect Exclusion criteria: Patients with psychotic features; addiction; anxiety disorders; age under18 and above65 years old; patients with hypertension, cardiac disease, urinary problems, cataract, increased eye pressure; patient with personality disorder and patients who are taking the other medications

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sweating. Timepoint: Before intervention, 2weeks after intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Sherafat.zahra

Farshchian hospital.

z.sherafat@umsha.ac.ir+98 81 1828 5015

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026